Cleveland Diagnostics Announces Prostate Cancer Awareness Month Campaign: ‘A PSA on PSA’

CLEVELAND – (August 30, 2023) – Cleveland Diagnostics, Inc., a leading commercial-stage biotechnology company, is launching its inaugural Prostate Cancer Awareness Campaign this September: ‘A PSA on PSA.’

Short for ‘A Public Service Announcement on the Prostate-Specific Antigen,’ the campaign will kick off on September 1. Throughout the entire month, patients, families, and caregivers are encouraged to download a fact sheet filled with helpful information and resources to help better navigate prostate cancer screening, diagnoses, and treatment options. For every fact sheet download, Cleveland Diagnostics will make a donation to ZERO Prostate Cancer to fund research and other important support initiatives. During the month of September, donations will be doubled by Golf Fights Cancer in celebration of the awareness month.

“Our ‘A PSA on PSA’ campaign is a public service initiative designed to drive those important patient-provider conversations and get more patients screened for prostate cancer,” shared Arnon Chait, PhD, President and CEO at Cleveland Diagnostics. “With increased education and awareness around accurate screening, we should be able to detect prostate cancer earlier and save more lives. And, through our partnership with ZERO, we hope to continue to advance the field via important research and accessibility programs.”

One in every eight men will be diagnosed with prostate cancer in their lifetime, making it the second most common cancer in men, according to the American Cancer Society. Starting at age 50, men can get screened for prostate cancer every two years, unless a higher PSA (prostate-specific antigen) level is detected. A higher PSA level typically leads to additional testing, with varying levels of invasiveness and accuracy ranging from blood tests to biopsies.

"By collaborating with Cleveland Diagnostics on the 'A PSA on PSA' campaign, we are empowering men to take charge of their prostate health. This educational initiative will promote vital conversations to help save lives. We appreciate the support of Cleveland Diagnostics in our mission to make ZERO Prostate Cancer a reality," added Colony Brown, Chief Marketing Officer of ZERO.

Cleveland Diagnostics’ mission is to transform cancer diagnostics through next-generation diagnostic tests. Its novel IsoPSA test is a non-invasive, blood-based test that provides greater insight into patients’ elevated PSA levels. This cancer-specific, PSA-based test is critical for early cancer detection in many patients while minimizing the overdiagnosis and overtreatment of others.

The physician-ordered IsoPSA test is now available to order directly through Cleveland Diagnostics or at select Quest Diagnostics locations – the company announced an agreement with Quest Diagnostics earlier this year to expand patient access to IsoPSA.

For more prostate cancer information, stats, and resources, visit PSAonPSA.com

About Cleveland Diagnostics, Inc. Cleveland Diagnostics, Inc. is a commercial-stage diagnostics company developing highly efficacious, lab-friendly, affordable diagnostics tests using proprietary technology to improve cancer diagnostics. The Company’s Solvent Interaction Analysis™ (SIA) technology investigates protein biomarkers at the structural level in blood, providing better and more direct insights regarding the protein origin on the cellular level, thus improving test specificity to the underlying disease process. Its portfolio of non-invasive cancer diagnostics will be expanding from prostate cancer to additional cancers. Please visit us at ClevelandDx.com.